A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer

The purpose of this study is to find out the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDEs) of JNJ-101684362 (HLD-0117), to evaluate the safety of JNJ-101684362 (HLD-0117) , and how well the participants can tolerate it in Part 1 (dose escalation) of the study.

Trial Details

NCT ID
NCT07524855
Phase
PHASE1
Sponsor
Janssen Research & Development, LLC
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • JNJ-101684362 (HLD-0117)
Locations (sample)
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Sarasota, Florida, United States|27.33643,-82.53065
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Nashville, Tennessee, United States|36.16589,-86.78444
  • San Antonio, Texas, United States|29.42412,-98.49363

Key Eligibility Criteria

  • Female (assigned at birth), greater than or equal to (\>=) 18 years old, and able to provide informed consent
  • Histologically confirmed metastatic or locally advanced breast cancer
  • Postmenopausal status defined by surgical or natural menopause, or ovarian suppression with a GnRH agonist
  • Prior therapy including

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →